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There are abundant reports on the use of aromatic amino acids and creat-
inineas biomarkers in serum and urine forCKD(chronic kidney disease). 
However, investigationsinto these bio-species in bio- uids, such as saliva 
and sweat, are rarely reported. Increasing interest in non-invasive methods 
for medical diagnosis advocates for the testing of these bio- uidstoiden-
tify potential biomarkers for prompt clinical andpreliminary screening 
using advanced analytical equipment. Unstimulated whole saliva samples 
were obtained from twenty-seven CKD patients and an equivalent num-
ber of healthy individuals. Saliva was assayed with ultra-performance liq-
uid chromatography coupled with electro-spray ionization tandem mass 
spectrometry (UPLC-ESI-MS) in hydrophilic interaction chromatography 
mode. The data were analyzed using a student’s t test and receiver op-
eratingcharacteristic (ROC) to evaluate the predictive power of several 
potential biomarkers (P<0.01) in saliva for preliminary CKD screening. 
Through testing of salivary samples between CKD patients and healthy 
individuals, we found three possible salivary biomarkers that demon-
strated signi cant differences (P<0.01) from the nine reported species in 
serum and/or urine. The area under the curve (AUC) values for control vs 
CKDpatientsfor on L-phenylalanine, L- tryptophan, and creatinine were 
0.863, 0.834, and 0.916, respectively. This is the  rst report to compare 
serum and urine biomarkers in saliva between CKD patients and healthy 
people. This study explores the potential of CKD diagnosis by saliva, and 
demonstrates a positive correlation between salivary and serum creati-
nine.
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1. Introduction
C
hronic kidney disease (CKD) is considered to be 
a part of the rising non-communicable disease 
burden worldwide. Prevalence of CKD is estimat-
ed to be 8-16% world-wide[1]. Important risk factors for 
CKD include hypertension, diabetes mellitus, and obesity. 
Treatment of CKD is often neglected by patients because 
of a delay in diagnosing indicators in common clinical 
experiments when compared totheprogression of the actu-
al pathological process. Recently, a comparison between 
control group and healthy group has becomeanincreasing-
ly attractive and important goal. 
Currently, biomarkers for CKD are often detected in 
serum and/or urine using various types of equipment, but 
this is not ideal becausethereisdiminishedcompliance of 
patients for these methods of sample collection. Moreover, 
frequent collection of blood during dialysis is particularly 
adverse for the elderly and infants. Thus,it is advantageous 
for investigators to developadditional means of a non-in-
vasivemethod. One such method that should be tested for 
potential diagnostic ability is the use of bio uidssuch as 
saliva and sweat. Undoubtedly, saliva is the best option 
for a diagnostic alternative because of its safety and com-
fort in collection process. Sincemany compounds in blood 
make their way into saliva,it is a suitable indicator of the 
current state of the blood. A number of biomarkers that are 
used as indicators of pathophysiological states to differ-
entiate between patients and healthy people can be readily 
found in saliva[2].For example, decreased eGFR (estimated 
glomerular filtration rate) indicates a reduction in renal 
clearance of a variety of proteins and nitrogenous byprod-
ucts that could be detrimental to the vascular system[3].
Upon activation of apoptosis, the endothelium sheds 
micro-particlesthat are regarded asbiomarkers of endothe-
lial dysfunction[4] and are believed to behave as bioactive 
vectors[5]. The metabolism of amino acids is related to 
the function of kidney, therefore regarding abnormalities 
of amino acids discovered in CRF can show the loss of 
renal function[6]. Therefore, we can compare biomarkers 
identified byultraperformance liquid chromatography 
coupled to a electrospray ionization mass spectrome-
try(UPLC-ESI-MS) with diagnostic standard compounds 
and determine whether saliva could be an alternative 
medium to serum and urine for patients with CKD. The 
components of blood that are exchanged in the kidney can 
also be exchanged in salivary glands, so the concentra-
tions of biomarkers in blood and urine may correlate with 
those in saliva. Furthermore, it would be a quicker, easier, 
and cheaper alternative for medical testing and diagnosis. 
However, factors such as the collection method, collec-
tion time, sex, body mass index, weight, and smoking can 
affect the global metabolite profiles of patients[7]. Dis-
eases that have been previously reported to bene t from 
the application of saliva as a diagnostic tool range from 
cancer to other metabolic diseases, including periodontal 
disease[8], oral and breast cancers[9-12], and Sjögren’s syn-
drome[13].
Nevertheless, salivary biomarkers of CKD certainly 
need to be compared with those discovered in serum and 
urine samples although saliva seems to have an attractive 
future in clinical research, pathology, and therapy. Since 
most of the compounds of these biomarkers are hydro-
philic, we utilized UPLC-ESI-MS to focus on these com-
pounds with a metabolic approach. 
UPLC which uses high pressure and small diameter 
porous particles and is combined with electrospray ioniza-
tion time of  ight mass spectrometry enables us to obtain 
the properties of compounds with a higher peak capacity, 
better resolution, increased sensitivity, and greater selec-
tivity at a high acquisition rate. This detection method is 
especially advantageous for detecting accurate molecules 
of polar compounds.
While genomics, transcriptomics, and proteomics can 
provide diagnostic support for various diseases, metabo-
lomics can generate the greatest differentiation of com-
pounds. Currently, there are few investigations reporting 
metabolites of saliva from CKD patients using UPLC-
ESI-MS. Therefore, in this study, we aimed to validate 
salivary biomarkers of CKD patients using UPLC-ESI-
MS for a general screening of CKD biomarkers currently 
utilized in serum and urine samples, and thus, con rm the 
potential of saliva for CKD diagnosis.
2. Materials and Methods
2.1 Materials
Acetonitrile (HPLC grade) was provided by Burdick & 
Jackson (USA). Distilled water was produced “in-house” 
utilizing an ULUPURE system (Chengdu Ultrapure Tech-
nology Co., Ltd, Chengdu, China). Ammonium formate 
was UPLC grade obtained from Adamas (Switzerland). 
Creatinine was from CNW(Shanghai).
L-phenylalanine and L-tryptophan were bought from 
Sangon(Sangon Biotech Co., Ltd, Shanghai, China). The 
stock standard solutions 0.2mg/mL of L-phenylalanine, 
L-tryptophan, and creatinine were prepared by dissolving 
L-phenylalanine, L-tryptophan, and creatinine in aceto-
nitrile/water with 0.05% formic acid, respectively. These 
solutions were stored at 2-8 °C and the mix solvents ace-
tonitrile/water prior to use were employed through dilut-
ing the stock solutions to obtain the respective concentra-
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tions with.
2.2 Subjects
Patients suffered from CKD were foundin the West China 
Hospital of Nephrology. All the volunteers included 27 
CKD patients and 27healthy volunteers. Patients (non-
smokers) who have cancer, cardiac insuf ciency, alimen-
tary tract hemorrhage, respiratory failure or other diseases 
are excluded due to the fact that may have an impact on 
the biological indicators and clinical observations. The 
Ethics Committee of Sichuan University approved the 
study protocol which was carried out according to the 
Helsinki Declaration of 1975. All patients are Chinese, 
and a consent form was obtained and concurred to be re-
sponsible as the saliva donors of the experiments.
For patients with CKD without dialysis, participation 
was allowed if the serum creatinine clearance was below 
than 59 mL/min/1.73m2 (measured directly by clearance 
technique). Twenty-seven healthy adults without histo-
ry of diabetes mellitus, kidney disease or other diseases 
consisted of subjects, and were tested clinically at recruit-
ment.
2.3 Saliva Collection and Sample Preparation
After fasting overnight, all the subjects were required to 
avoid eating, drinking, smoking, and oral hygiene proce-
dures for at least several hours before sample’s collection. 
We obtained 2-4 mL of clear un-stimulated whole sa-
liva between 9:00 and 11:00 a.m. venous blood samples 
were drawn from all patients from the antecubital vein 
(for CKD patients). Saliva was then sent to the laboratory 
for isolation. We added 400μL of the processed saliva to 
a mixture of methanol/ acetonitrile (1:3 v/v, 800 μL) to 
precipitate the proteins, before vigorous shaking for about 
60s. Samples were then vortexed for at 13500 rpm for 21 
min at 4 °C. After allowing samples to stand at the same 
temperature for 10 min, the supernatant was taken for UP-
LC-ESI-MS’ analysis.
2.4 UPLC-ESI-MS Analysis
The identifications were performed on the UPLC-ESI-
MS system consisting of a Waters ACQUITYTM Ultra 
Performance Liquid Chromatography system and a Mi-
cromassLCT Premier TM orthogonal accelerated time of 
 ight mass spectrometer (Waters, Milford, USA).
The chromatographic separation was achieved with an 
ACQUITY UPLC BEH Amide column (100mm*2.1mm 
i.d, 1.7um, Waters, Milford, USA) with the sample tem-
perature set to 8 °C. 
The column is eluted utilizing with the solvent sys-
tem as below with the  ow rate as 0.15mL/min: (A) 95:5 
acetonitrile-aqueous ammonium acetate (10mmol/L), (B) 
50:50 acetonitrile-aqueous ammonium acetate (2mmol/l). 
After every injection, the auto-sampler was cleaned with a 
strong/weak wash cycle to remove residue. Each run took 
20 minutes.
TOF/MS was performed using an ESI source, operat-
ing in positive ion mode. The data pro le of positive ions 
ranges from m/z 50-1000. The capillary voltage was 3.2 
kV in positive mode; the cone voltage was 30 V. The de-
solvation gas  ow was set to 650 L/h at a temperature at 
350 °C. The cone gas  ow was obtained as 30L/h, and the 
source temperature was 110 °C.
In the recent study, intact mass data can be acquired 
using the TOF mass spectrometer  tted with alock spray 
enabled Z-spray ion source. A lock mass of leucine en-
kephalin (Sigma-Aldrich, L9133, lot 095K5109, Stein-
heim,Germany, [LE+ H]+, m /z, 556.2771) for positive 
ion mode was utilized to correct lock mass. The solution 
of LE was ivia a lock spray interface at the  ow rate of 0.05 
mL/min with the help of a second LC pump (Waters). 
2.5 Data Processing and Analysis
A multivariate data can be identified by integrating and 
deconvoluting the mass spectral data matrix incorporat-
ing an integrated peak area for measured features (unique 
mass-retention time pair) by alignment, peak picking and 
deisotoping employing MassLynx 4.1 (WatersCorp, Mil-
ford, MA).The raw data were found correspounding to 
a multivariate matrix containing aligned peak areas with 
matched retention times and mass-to-charge ratios (m/z). 
The distinctions of metabolites in both saliva biomarkers’ 
intensity in two groups were analyzed with the Students’ 
T test.
The Students’ T test was utilized to examine vital dis-
tinctions in the distributions between control group and 
CKD group. Then to estimate the diagnostic effectiveness 
of both possible biomarkers such as L-phenylalanine, 
L-tryptophan and creatinine with 95% confidence inter-
val (CI) for CKD recognition and to  nd out a best cut-
off based on the maximum corresponding speci city and 
sensitivity receiver operating characteristic (ROC) curves 
were also used. Two-tailed p<0.01 was taken to be re-
markably signi cant.
This equipment’s relative standard deviations (RSD) of 
peak areas and retention times about the sample of saliva 
were qualified, and so were the standard materials. The 
system stability is shown from the predicting data of QC 
sample. It proved that the developed method had good re-
peatability and stability. The healthy group was comprised 
of 27 healthy volunteers.Therewere17 males and 10 fe-
DOI: https://doi.org/10.30564/jams.v2i3.640
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males. Patient group comprised 27 CKD patients,andthere 
were 16 males and 11 females.
3 Results and Discussions
3.1 Patients Descriptions
All 27 patients recruited in this research were pathologi-
cally and clinically diagnosed with CKD. No signi cant 
distinctions between CKD patientsand the control group 
can be seen in measurements of 7-ketolithocholic acid, 
choline, creatine, adenine, guanine, and betaine (7-ke-
tolithocholic acid: P=0.022; choline: P=0.036; creatine: 
P=0.229; adenine: P=0.010; guanine: P=0.427; betaine: 
P=0.012). SIM (selected ion monitoring) showed that ac-
curate molecular weights were provided for the 9 salivary 
biomarkers found in serum and urine and were fully sepa-
rated with the correct gradient program.
Figure1. Raw BPI of UPLC-MS data obtained from the 
saliva sample of health and CKDgroup at positive ESI 
mode
3.2 Linearity and Limit of Quantitation
In order to accurately evaluate the linearity of L-phenyl-
alanine, L-tryptophan, and creatinine, each type of them 
was added to salivary sample at the concentrations of 0, 
10, 30, 50, 150, 200, 300 ng/mL. The calibration pro le 
was established by endogenous L-phenylalanine, L-tryp-
tophan, and creatinine levels’ subtraction from added 
saliva specimen. This assay was found to be linear up to 
1000 ng/mL for all three biomarkers. The linear equations 
of calibration curves of L-phenylalanine, L-tryptophan, 
and creatinine in human saliva were y=2.003*x+555.367 
with r2=0.990, y=0.482*x+19.358 with r2=0.999, an-
dy=0.835*x-31.094 with r2=0.994, respectively (y, peak 
area; x, concentration (ng/mL) of L-phenylalanine, 
L-tryptophan and creatinine; r, correlation coefficient). 
Under our UPLC-ESI-MS conditions, the limits of detec-
tion (LOD, S/N=3) of L-phenylalanine, L-tryptophan, and 
creatinine were 3.39, 15.54, and13.32ng/mL, respectively. 
The limit of quantification (LOQ) was explained as the 
level when the S/N ratio is 10. Therefore, LOQ was 11.31, 
51.78 and 44.40 ng/mL for L-phenylalanine, L-tryptophan, 
and creatinine, respectively.
P<0.001
P<0.001
p=0.001
B. L-tryptophan C. CreatinineA. L-phenylalanine
Figure2. Box plots of the three biomarkers in differenti-
ating CKD group from healthy group and the P values of 
the comparing of CKD with control were marked
Figure 3. ROC analysis for three biomarkers in diagnosis 
of CKD
Table 1. Identi cation and Quanti cation of biomarkers 
of CKD patients found in saliva and reported[23] in serum 
and/or urine
Name
Retention 
Time
Pattern 
[M+H]
Actual 
Mass
Exact 
Mass
Mass 
Error
P
7-Ke-
tolitho-
cholic 
acid
1.56 C24H39O4 391.2884 391.2848 3.6 0.022
Phenyl-
alanine
7.54 C9H12NO2 166.0860 166.0868 -0.8 <0.001
Trypto-
phan
7.21
C11H-
13N2O2
205.0966 205.0977 -1.1 0.001
Choline 7.02 C5H15NOd 104.1060d 104.1061 0.7 0.036
Creatine 9.11
C4H-
10N3O2
132.0761 132.0767 -0.6 0.229
Creati-
nine 
4.33 C4H8N3O 114.0667 114.0660 -1.6 <0.001
Adenine 6.23 C5H6N5 136.0607 136.0623 0.1 0.010
Guanine 10.71 C5H6N5O 152.0573 152.0572 -0.5 0.427
Betaine 4.84 C5H12NO2 118.0863 118.0868 -0.7 0.012
Notes: aSelected peak [M-H2O+H]
DOI: https://doi.org/10.30564/jams.v2i3.640
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Table 2. Remarkable salivary biomarkers’ ROC curve 
analysis
Metabo-
lites
Aucs
95%Confdence 
Interval
Sensitivity Specifcity
Std. Erro-
ra
Phe 0.863 0.725-0.970 0.926 0.741 0.055
Trp 0.861 0.762-0.961 0.815 0.815 0.051
Creati-
nine
0.916 0.832-1.000 0.926 0.741 0.056
LR mod-
el
0.936 0.856-1.015 0.889 0.926 0.040
Notes: aUnder the nonparametric assumption
3.3 Human Saliva Analysis
Saliva samples from 27 healthy individuals and 27 CKD 
patients were analyzed. We first measured the levels 
of the three metabolite biomarkers used to distinguish 
CKD from control. Figure 1 shows a typical BPI (base 
peak ion) of a saliva sample from both a healthy indi-
vidual and a CKD patient (TRA=7.86min; cTRB=7.35min; 
TRC=4.63min). Figure 2 demonstrates that the concentra-
tions of these 3 biomarkers in CKD subjects were signi -
cantly higher than that of healthy individuals. Students’ 
t-Tests were employed to study the distinctions’ statistical 
signi cance in the distributions between the control group 
and CKD group and P<0.01 was thought to be remarkably 
signi cant (two-sided). The Student’s t-Test is a paramet-
ric method and the p-values of these independent groups 
were marked in the  gures. As the result of the p-values 
in Figure 2, we discovered that the distributions of L-phe-
nylalanine, L-tryptophan, and creatinine in saliva samples 
were all significantly different (p<0.01). However, we 
found that the p-values of 7-ketolithocholic acid, choline, 
adenine, and betaine were all in the range of 0.01 to 0.05. 
In addition, the p values of creatine and guanine were 
larger than 0.05 in these two groups. Therefore, the differ-
entiation power of creatine and guanine is weakest among 
all the biomarkers, and L-phenylalanine, L-tryptophan, 
and creatinine were the most promising biomarkers using 
this analytical technology. We will get further diagnostic 
power for the most prominent three to compare their abili-
ty in discriminating two groups. 
To further investigate the diagnostic power of these 3 
biomarkers, their ROC curves were evaluated. The ROC 
curves were constructed using SPSS and can indicate a 
diagnostic test’s overall accuracy. In an excellent test, the 
relevant AUC value is 1.0 and with the angle’s top at the 
apex left of panel the ROC curve is a right angle. 
When AUC ranges from 0.5 to 0.7, which shows a rela-
tively low diagnostic value. An AUC above 0.9 is consid-
ered to be highly accurate. Figure 3 shows the curve of the 
remarkably signi cant salivary biomarkers, and a detailed 
AUC (95%CI), cutoff values, sensitivity and specificity 
are illustrated in Table 2. We found that L-phenylalanine, 
L-tryptophan, and creatinine have sensitivities and spec-
ificities of 0.926 and 0.815, 0.92 and 0.741, and 0.815 
and 0.741, respectively. Furthermore, the AUC values for 
L-phenylalanine, L-tryptophan, and creatinine were 0.863, 
0.861, and 0.916, respectively. These results indicate that 
amino acids including L-phenylalanine, L-tryptophan 
have a similar ef ciency as a biomarker as creatinine in 
the diagnosis of CKD. The AUC value for these 3 signif-
icant biomarkers in combination were 0.936 (sensitivi-
ty=0.889, speci city=0.926).
Figure 4. Correlation between saliva creatinine and serum 
creatinine
Figure 5. Summary of pathway analysis with MetPA
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Figure 6. Hierarchical clustering analysis of metabolites 
identi ed by standard substances between males and 
females
Figure 7. Construction of Glycine, serine and threonine 
metabolismmetabolism pathways in human CKD disease 
generated by KEGG.
3.4 Correlation between Saliva Creatinine and 
Serum Creatinine
To understand the relationship between serum and sal-
ivary creatinine and how to change it, we conducted 
a correlation analysis of the case groups. As shown in 
Figure 4, a signi cant correlation was indicated between 
serum creatinine levels and salivary creatinine concen-
trations(r=0.433, p<0.05). Low levels of salivary creat-
inine are associated with a high serum creatinine levels. 
Additionally, the mean serum and the salivary creatinine 
concentration were discovered to be significantly higher 
in CKD subjects in comparison with those in the controls. 
Serum creatinine is positively correlated with that of sali-
va in CKD patients with r = 0.507 (Figure 4).
3.5 Heatmap Analysis
Heatmap(Figure 6) directly observed the variation in 
men and women which re ects some biomarkers induced 
by the sex. Further evaluation is needed to validate the 
compound in these groups to provide a better diagnosis 
approach in patients.
3.6 Biochemical Analysis
Chenodeoxycholic acid is the main bile acid, and 7-keto-
lithocholic acid is regarded as the main intermediate in the 
intestinal bacterial transforming from chenodeoxycholic 
acid to ursodeoxycholicacid[14]. Zhao[15] et al found that 
in adenine-induced CRF(chronic renal failure) rats, the 
down-regulation of the 7-ketolithocholic acid is mostly 
based on the overgrowth of small-intestinal bacteria which 
causes deconjugation of bile acids and less efficient ab-
sorption.
Choline is a quaternary amino cationic alcohol that can 
be oxidized to betaine in the mitochondria of kidney cells. 
However, betaine might play a role reducing the risk of 
atherosclerosis in patients with CRF by decreasing the 
post methionine load hyper homocysteinemia[16]. Hen-
ricus[17] et al discovered the level of betaine’s oxide was 
elevated in stage 3-4 CKD patients.
For phenylalanine and tryptophan, daily diet can be the 
only way because these two necessary amino acids cannot 
be synthesized in vivo. LewenJia[18] et al demonstrated 
that and phenylalanine and tryptophan’s concentrations of 
CRF patients altered dramatically when compared with 
the control group due to the pathophysiology of CRF dis-
ease[19].
Slominska[20] et al indicated a close correlation between 
anincrease of adenine concentration in plasma from CRF 
patients and the adenine incorporation rate into eryth-
rocyte adenine nucleotide pool. Furthermore, plasma 
adenine concentration and its erythrocyte incorporation 
rate had a strong correlation with erythrocytes’ ATP lev-
els. Moreover, Hayashie[21] et al found that guanine levels 
were decreased in both serum and urine of patients among 
the serum and urine biomarkers of CKD individuals. In 
addition to phenylalanine, tryptophan and creatinine are 
also found in rats[22-24]. Thus, Larsen[25] et al even investi-
gated phenylalanine in dogs and rats with CKD. As shown 
in Table 1, previous research[26] about the biomarkers are 
included. The distribution of creatinine (P=0.229) and 
guanine (P=0.427) were not signi cantly different. 
Other compounds that are important for the pathways 
of metabolomics include phenylalanine metabolism, gly-
cine, serine and threonine metabolism, arginine and pro-
line metabolism, purine metabolism except 7-Ketolitho-
cholic acid (P=0.022). Both choline and betaine generate 
glycine, serine, and threonine metabolism. In serum andu-
rine they are statistically signi cant, and thus, are possible 
surrogate biomarkers for subjects with CKD. Phenylala-
nine belongs to necessary amino acids, and phenylalanine 
hydroxylation activity in the kidney appears to be similar 
or even greater than that across the splanchnic area. In 
DOI: https://doi.org/10.30564/jams.v2i3.640
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addition, phenylalanine hydroxylation of the whole body 
rates also markedly decreased in renal patients[27,28]. 
Tryptophan is different from other amino acids be-
cause it is largely protein bound. The mechanisms for 
abnormalities in tryptophan metabolism in kidney disease 
remain complex, but decreased absorption of intestine 
and increased catabolism of liver have been suggested[29]. 
Tryptophan metabolism may act signi cantly in the pro-
gression of CKD except nutritional consequences because 
changes of tryptophan level are potentially vital[30]. 
Tryptophan and phenylalanine can be absorbed only 
from diet. Our results illustrates that the signi cant level 
changes in both phenylalanin and tryptophan compared 
with the controls.
It is reported that this had relation to CRF disease’s 
pathophysiology[19].The kidney is included in tryptophan 
metabolism in these ways:1) tryptophan derivatives is 
eliminated by it and 2) numerous enzymes involved in 
tryptophan metabolism mainly through the kynurenine 
pathway are produced by it[31]. Thus it is unknown wheth-
er tryptophan exchange in organs involves bound or free 
tryptophan. However, the uptake of the brain’s tryptophan 
originated from blood seems to be dependent on bound 
ones[29]. When a meal containing meat or when a large 
amount of tryptophan is administered, the total concen-
tration of blood tryptophan do not rise as high as that in 
normal condition[32]. Uremia is another important bio- uid 
and altering in tryptophan metabolism appearing in ure-
mia may be considered as several causes: (1)Tryptophan 
play a critical role in the protein turnover’s regulation as it 
is an essential amino acid which has to be synthesized by 
absorbing protein; (2) The formation of neurotoxins may 
be included in tryptophan metabolism (i.e., quinolinic 
acid); and (3) It has been concluded that, except nutrition-
al results tryptophan, tryptophan metabolism may be a 
vital part in the progression of CKD.[30] Furthermore, oth-
er amino acids such histidine, arginine, taurine and valine 
are also required [33-35]. In contrast, our results differ from 
other serum and urine studies, which demonstrate grow-
ing levels of L-phenylalanine[36]. Recently, Jie Wei[37] et 
al showed that this discrepancy between saliva and serum 
may originate from different metabolite speeds in different 
biological compartments. Each biomarker has a specific 
abundance concentration in a given compartment that is 
affected by both in-vivo and in vitro patho-physiological 
stimuli. Despite the fact that these markers are from dif-
ferent metabolic pathways, they are able to share certain 
metabolites with the same path of perturbation partly be-
cause they have similar metabolic enzymes that associated 
with the development of kidney disease. There may also 
be other causes that this type of instrumentation is highly 
sensitive and various factors may affect the performance 
of the apparatus and he sensitivity[38].
Therefore, abnormalities in amino acids of uremia 
caused by CRF have been ascribed to toxic effects of 
uremia on the amino acids’ intermediary metabolism, low 
protein intake, deficient renal excretory and metabolic 
functions, loss of protein and amino acids by the dialysis 
procedure and changing distribution of some amino acids 
between the extra- and intra-cellular compartments[39]. 
These data in this essay may be valuable in understand-
ing the mechanism(s) of the changes in phenylalanine and 
tryptophan metabolism occurring in disease state. It may 
also provide a possible cause for poor nutritional status 
and reduced blood  ow that is often observed in uremia. 
Creatinine’s lipid solubility is very low excreted by the 
kidney and it is a waste product of metabolism[40] although 
its molecular mass is large. Virtually all the creatinine that 
is  ltered at the glomerulus is excreted without reabsorp-
tion in the tubules. Thus, the level creatinine in the blood 
is used as an index of renal function[41]. To determine if 
there is an association between serum and salivary cre-
atinine, a correlation analysis of the case groups were 
performed. We observed a positive correlation between 
serum and salivary creatinine in CKD patients (r=0.507). 
A positive correlation can be explained by the permeabili-
ty of salivary gland cells between the membranes[42], CKD 
patients have increased serum creatinine levels, which 
creates a concentration gradient that facilitates increased 
diffusion of creatinine from serum to saliva[43]. In fact,X-
ia[44] et al found a similar positive correlation in both their 
cases (r=0.971). Our investigation demonstrates that the 
level of salivary creatinine correlates with that of serum 
creatinine. As this may be due to different sources, the 
results of the present study imply a correlated relationship 
between serum creatinine and saliva creatinine rather than 
a causation[37].
The basic measurements of diagnostic test accuracy 
are sensitivity and speci city. Hence, ROC analysis was 
produced to determine the diagnostic potential of saliva as 
an alternative medium (Fig. 3).Accuracy is measured by 
the area under the ROC curve. The highest area under the 
curve (0.916) got in our study was for salivary creatinine. 
This suggests that the screening of salivary creatinine is a 
good alternative diagnostic test to discriminate CKD pa-
tients from healthy individuals.
 To the best of our knowledge, it is  rstly to investigate 
creatinine (P<0.01) and adenine (P=0.01) in saliva detect-
ed by UPLC-MS. This novel method of detecting metab-
olite salivary biomarkers of CKD is noninvasive, simple, 
fast, and comfortable. 
These results advise that the results of salivary bio-
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markers of CKD has the possibility to contribute to 
ground breaking advancements in molecule-oriented mon-
itoring and screening of CKD since its accuracy seems 
similar to traditional approaches. Thus, the proposed ap-
proach could complement conventional diagnostic method 
in preliminary screening. Moreover it may assist a quick, 
early and noninvasive diagnosis of CKD. However, obsta-
cles still remain, as age, sex of the samples and collection 
time might contribute to changes in the markers measured.
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